Effect of anlotinib combined with camrelizumab on clinical efficacy and short-term prognosis in male patients with advanced gastric cancer

Abstract

This study aimed to investigate the effects of combining anlotinib with camrelizumab on clinical efficacy and short-term prognosis in male patients with advanced gastric cancer. A total of 88 male patients admitted to our hospital between May 2019 and March 2022 with advanced gastric cancer were included and randomly assigned to Group A (treated with anlotinib alone) or Group B (treated with anlotinib combined with camrelizumab) using the envelope method, with 44 patients in each group. Their clinical efficacy, vascular endothelial growth factor (VEGF) and programmeddeath-1 (PD-1) expression on Cluster of differentiation 4+ (CD4+) and cytotoxic Tlymphocyte (CD8+ T) cells in peripheral blood, immune function parameters, tumor markers, incidence of adverse reactions and survival time were compared. The results showed that the patients in Group B had significantly higher objective response rate (ORR) and disease control rate (DCR), superior PD-1 in VEGF, CD4+ T cells and CD8+ T cells, significantly improved immune function indicators and tumor markers (Carbohydrate antigen 50 (CA50), carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1)), and significantly longer progression-free survival and overall survival than Group A. In addition, no significant difference in the incidence of adverse reactions between the two groups was observed. Therefore, the combination of anlotinib and camrelizumab could be a clinically beneficial treatment option and recommended for male patients with advanced gastric cancer as it can effectively control tumor progression, improve clinical efficacy and prolong their survival without increasing adverse reactions.

Keywords

• anlotinib
• camrelizumab
• male
• advanced gastric cancer
• clinical efficacy
• short-term prognosis